.After a few years in biotech, Mike Quigley, Ph.D., is actually returning to the pharma crease, using up the leading scientific research area at Sanofi.Quigley will definitely start Sept. 30 as the French Big Pharma’s chief medical officer and international chief of research study, Sanofi told Ferocious Biotech in an emailed declaration.Quigley is actually substituting Frank Nestle, M.D., who left Sanofi this springtime among an international overhaul of the provider’s R&D device. Nestle, that devoted eight years along with the pharma, leapt over to Deerfield Control, where he currently works as a companion on the therapies team and chief executive officer of the agency’s restorative discovery and also growth operations.
Quigley will definitely join Sanofi coming from a San Francisco-based biotech that remains in secrecy, according to his LinkedIn profile. He’s currently provided as the company’s founder, head of state as well as CEO.Because August 2021, Quigley has acted as a project companion at SV Health Investors, a medical care fund supervisor with current financial investments in biotechs such as BioAge, Cerevance, Dualitas Therapeutics as well as Nimbus Therapeutics, and many more. Quigley previously stored the top spot at Dualitas, a biotech that remains in secrecy, according to STAT.The prospective Sanofi leader additionally formerly helmed Therini Biography, an immunotherapy biotech operating to create treatments for neurodegenerative illness driven through vascular problems.Before devoting the final handful of years in biotech, Quigley has an even longer performance history in Big Pharma, most lately working as Gilead’s senior bad habit head of state of study the field of biology until the summer of 2021.
Just before that, he clocked in much more than 4 years throughout different management tasks at Bristol Myers Squibb as well as functioned as a medical supervisor at Johnson & Johnson’s Janssen arm just before that.Sanofi said Quigley’s mission in his new duty would certainly be to “optimize our chance of excellence through optimum collaborations all over our association and also past, taking best-in-class innovation and also building and also sourcing brand new industry-leading ability with a commitment to diversity,” according to an internal memo gotten by STAT.